In vitro effects of meloxicam with or without doxorubicin on canine osteosarcoma cells

Journal of Veterinary Pharmacology and Therapeutics

Volumn 29, Issue 1, 2006, Pages 15-23

  Wolfesberger, B ^a   Hoelzl, C ^a   Walter, I ^a   Reider, G A ^b   Fertl, G ^c   Thalhammer, J G ^a   Skalicky, M ^a   Egerbacher, M ^a  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b VIENNA UNIVERSITY OF TECHNOLOGY   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DOXORUBICIN; MELOXICAM; ANTINEOPLASTIC ANTIBIOTIC; PROSTAGLANDIN SYNTHASE INHIBITOR; THIAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL CELL; ARTICLE; BONE TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOG; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; ENZYME INHIBITION; GROWTH INHIBITION; NONHUMAN; OSTEOSARCOMA CELL; PRIORITY JOURNAL; TUMOR GROWTH; WESTERN BLOTTING; ANIMAL; CELL CULTURE; DOSE RESPONSE; OSTEOSARCOMA;

ANIMALIA; CANIS FAMILIARIS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BONE NEOPLASMS; CYCLOOXYGENASE INHIBITORS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SYNERGISM; OSTEOSARCOMA; THIAZINES; THIAZOLES; TUMOR CELLS, CULTURED;

EID: 33644849927     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2006.00704.x     Document Type: Article

References (58)

1. Aapro M.S. Alberts D.S. Salmon S.E. 1983 Interactions of human leucocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. Cancer Chemotherapy and Pharmacology 10 161 166.
2. Alexander J.W. Patton C.S. 1983 Primary tumors of the skeletal system. Veterinary Clinics of North America Small Animal Practice 13 181 195.
3. Berg J. Weinstein M.J. Dempsey S. Rand W.M. 1995 Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. Journal of the American Veterinary Medical Association 206 1555 1560.
4. Bosetti C. Gallus S. La Veccia C. 2002 Aspirin and cancer risk: an update to 2001. European Journal of Cancer Prevention 11 535 542.
5. Bradford M.M. 1976 A rapid and sensitive method for the quantification of microgram quantise of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72 248 254.
6. Busch U. Schmid J. Heinzel G. Schmaus H. Baierl J. Huber C. Roth W. 1998 Pharmacokinetics of meloxicam in animals and the relevance to humans. Drug Metabolism and Disposition 26 576 584.
7. Chandrasekharan N.V. Dai H. Roos K.L. Evanson N.K. Tomsik J. Elton T.S. Simmons D.L. 2002 COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proceedings of the National Academy of Sciences 99 13926 13931.
8. Chen W.S. Wei S.J. Liu J.M. Hsiao M. Kou-Lin J. Yang W.K. 2001 Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2 selective inhibitor, etodolac. Internal Journal of Cancer 91 894 899.
9. Cipák L. Paulíková H. Novotný L. Jarosavá M. Rauko P. 2004 Potentiation of doxorubicin-induced apoptosis and differentiation by indomethacin in K-562 leukemia cells. Neoplasma 51 188 192.
10. Dickens D.S. Kozielski R. Khan J. Forus A. Cripe T.P. 2002 Cyclooxygenase-2 expression in pediatric sarcomas. Pediatric and Developmental Pathology 5 356 364.
11. Duffy C.P. Elliot C.J. O'Connor R.A. et al. 1998 Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of nonsteroidal anti-inflammatory drugs. European Journal of Cancer 34 1250 1259.
12. Eberhart C.E. Coffey R.J. Radhika A. Giardiello F.M. Ferrenbach S. DuBois R.N. 1994 Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 1183 1188.
13. Engelhardt G. Bögel R. Schnitzer C. Utzmann R. 1996 Meloxicam: Influence on arachidonic acid metabolism. Part 1. in vitro findings. Biochemical Pharmacology 51 21 28.
14. Farrow D.C. Vaughan T.L. Hansten P.D. et al. 1998 Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiology, Biomarkers and Prevention 7 97 102.
15. Folkman J. 2003 Fundamental concepts of the angiogenic process. Current Molecular Medicine 3 643 651.
16. Fosslien E. 2000 Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Critical Reviews in Clinical Laboratory Sciences 37 431 502.
17. Gately S. Li W.W. 2004 Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Seminars in Oncology 31 2 11.
18. Harris R.E. Chlebowski R.T. Jackson R.D. Frid D.J. Ascenseo J.L. Anderson G. Loar A. Rodabough R.J. White E. McTiernan A. 2003 Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Research 63 6096 6101.
19. Hattori K. Matsushita R. Kimura K. Abe Y. Nakashima E. 2001 Synergistic effect of indomethacin with adriamycin and cisplatin on tumor growth. Biological and Pharmaceutical Bulletin 24 1214 1217.
20. Hida T. Yatabe Y. Achiwa H. Muramatsu H. Kozaki K. Nakamura S. Ogawa M. Mitsudomi T. Sugiura T. Takahashi T. 1998 Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Research 58 3761 3764.
21. Hoang B.H. Dyke J.P. Koutcher J.A. Huvos A.G. Mizobuchi H. Mazza B.A. Gorlick R. Healy J.H. 2004 VEGF expression in osteosarcoma correlates with vascular permeability by dynamic MRI. Clinical Orthopaedics and Related Research 426 32 38.
22. Holick C.N. Michuad D.S. Leitzmann M.F. Willett W.C. Giovannucci E. 2003 Aspirin use and lung cancer in men. British Journal of Cancer 89 1705 1708.
23. Hwang D. Scollard D. Byrne J. Levine E. 1998 Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. Journal of the National Cancer Institute 90 445 460.
24. Kis B. Snipes J.A. Busija D.W. 2005 Acetaminophen and the COX-3 puzzle: Sorting out facts, fictions and uncertainties. Journal of Pharmacology and Experimental Therapeutics 315 1 7.q8
25. Kitagawa T. Ku Y. Kusunoki N. Tominaga M. Maeda I. Fukumoto T. Iwasaki T. Kuroda Y. Saitoh Y. 1996 Pharmacokinetics of intravenous adriamycin for anhepatic chemotherapy during liver transplantation. Transplant International 9 105 108.
26. Knapp D.W. Richardson R.C. Chan T.C. Bottoms G.D. Widmer W.R. De Nicola D.B. Teclaw R. Bonney P.L. Kuczek T. 1994 Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. Journal of Veterinary Internal Medicine 8 273 278.
27. Knapp D.W. Chan T.C.K. Kuczek T. Reagan W.J. Park B. 1995 Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells. American Journal of Veterinary Research 56 801 805.
28. Knottenbelt C.M. Simpson J.W. Tasker S. Ridyard A.E. Chandler M.L. Jamieson P.M. Welsh E.M. 2000 Preliminary clinical observations on the use of piroxicam in the management of rectal tubulopapillary polyps. Journal of Small Animal Practice 41 393 397.
29. Koga H. Sakisaka S. Ohishi M. et al. 1999 Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 29 688 696.
30. Laemmli U.K. 1970 Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 680 685.
31. Lees P. Landoni M.F. Giraudel J. Toutain P.L. 2004 Pharmacodynamics and pharmacokinetics of nonsteroidal anti-inflammatory drugs in species of veterinary interest. Journal of Veterinary Pharmacology and Therapeutics 27 479 490.
32. Li X.H. Li X.K. Cai S.H. Tang F.X. Zhong X.Y. Ren X.D. 2003 Synergistic effects of nimesulide and 5-fluorouracil on tumor growth and apoptosis in the implanted hepatoma in mice. World Journal of Gastroenterology 9 936 940.
33. Mauldin G.E. Fox P.r. Patnaik A.K. Bond B.R. Mooney S.C. Matus R.E. 1992 Doxorubicin- induced cardiotoxicosis. Clinical features in 32 dogs. Journal of Veterinary Internal Medicine 6 82 88.
34. Moalic S. Liagre B. Le Bail J.C. Beneytout J.L. 2001 Dose-dependent modulation of apoptosis and cyclooxygenase-2 expression in human 1547 osteosarcoma cells by NS-398, a selective cyclooxygenase-2 inhibitor. Internal Journal Oncology 18 533 540.
35. 2 concentrations in naturally occurring canine cells, Prostaglandins. Leukotrienes Essential Fatty Acids 64 1 4.
36. Mohammed S.I. Khan K.N.M. Sellers R.S. Hayek M.G. DeNicola D.B. Wu L. Bonney P.L. Knapp D.W. 2004 Expression of cyclooxygenase-1 and 2 in naturally-occurring canine cancer. Leukotrienes Essential Fatty Acids 70 479 483.
37. Mullins M.N. Lana S.E. Dernell W.S. Ogilvie G.K. Withrow S.J. Ehrhart E.J. 2004 Cyclooxygenase-2 expression in canine appendicular osteosarcomas. Journal of Veterinary Internal Medicine 18 859 865.
38. Munkarah A.R. Genhai Z. Morris R. Baker V.V. Deppe G. Diamond M.P. Saed G.M. 2003 Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells. Gynecologic Oncology 88 429 433.
39. O'Neill G.P. Ford-Hutchinson A.W 1993 Expression of m-RNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Letters 330 156 160.
40. Priester W.A. Mc Kay F.W. 1980 The occurence of tumors in domestic animals. Journal of the National Cancer Institute Monographs 54 1 210.
41. Quin N. Zhang S.P. Reitz T.L. Mei J.M. Flores C.M. 2005 Cloning, expression and functional characterization of human COX-1 splicing variants: evidence for intron 1 retention. Journal of Pharmacology and Experimental Therapeutics E-pub ahead of print.q9
42. Simon D. Knebel J.W. Baumgaertner W. Aufderheide A. Meyer-Lindenberg A. Nolte I. 2001 In vitro efficacy of chemotherapeutics as determined by 50% inhibitory concentrations in cell cultures of mammary gland tumors obtained from dogs. American Journal of Veterinary Research 62 1825 1830.
43. Smith G. Carey F.A. Beattie J. Wilkie M.J. Lightfoot T.J. Coxhead J. Garner R.C. Steele R.J. Wolf C.R. 2002 Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America 99 9433 9438.
44. Spirio L.N. Dixon D.A. Robertson J. Robertson M. Barrows J. Traer E. Burt R.W. Leppert M.F. White R. Prescott S.M. 1998 The inducible prostaglandin biosynthetic enzyme, cyclooxygenase 2, is not mutated in patients with attenuated adenomatous polyposis coli. Cancer Research 58 4909 4912.
45. Tsubouchi Y. Mukai S. Kawahito Y. Yamada R. Kohno M. Inoue K. Sano H. 2000 Meloxicam inhibits the growth of non-small cell lung cancer. Anticancer Research 20 2867 2872.
46. Tsujii M. DuBois R.N. 1995 Alterations in cellular adhesions and apoptosis in epithelial cells overexpressing prostaglandin endoperoxidase synthase 2. Cell 83 493 501.
47. Tsujii M. Kawano S. DuBois R.N. 1997 Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proceedings of the National Academy of Sciences 94 3336 3340.
48. Tsujii M. Kawano S. Tsuji S. Saeaoka H. Hori M. DuBois R.N. 1998 Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93 705 716.
49. Tucker O.N. Dannenberg A.J. Yang E.K. et al. 1999 Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Research 59 987 990.
50. Vane J.R. Mitchell J.A. Appleton I. Tomlinson A. Bishop-Bailey D. Croxtall J. Willoughby D.A. 1994 Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proceedings of the National Academy of Sciences 91 2046 2050.
51. Wallace J.L. Devchand P.R. 2005 Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense. British Journal of Pharmacology 145 275 282.
52. Waskewich C. Blumenthal R.D. Li H. Stein R. Goldenberg D.M. Burton J. 2002 Celecxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Research 62 2029 2033.
53. Williams C.S. Watson A.J.M. Sheng H. Helou R. Shao J. DuBois R.N. 2000 Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Research 60 6045 6051.
54. Winchester S.K. Imamura T. Gross G.A. Muglia L.M. Vogt S.K. Wright J. Watanabe K. Tai H-H. Muglia L.J. 2002 Coordinate regulation of prostaglandin metabolism for induction of parturition in mice. Endocrinology 143 2593 2598.
55. Wolfesberger B. Walter I. Hoelzl C. Thalhammer J.G. Egerbacher M. 2005 Antineoplastic effect of the cyclooxygenase inhibitor meloxicam on canine osteosarcoma cells. Research in Veterinary Science E-pub ahead of print.q10
56. Yamazaki R. Kusonoki N. Matsuzaki T. Hashimoto S. Kawai S. 2002 Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Letters 531 278 284.
57. Yang D.J. Bryant J. Chang J.Y. et al. 2004 Assessment of cyclooxygenase-2 expression with Tc-labeled celebrex. Anti-Cancer Drugs 15 255 263.
58. Yoshino S. Okabe T. 2003 Advance renal cell carcinoma in which a combination of IFN-α and meloxicam was thought to be affective. International Journal of Urology 10 52 55.